Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

Genetics or hormonal changes can pose challenges for losing weight, as you may know firsthand. Like many others struggling to ...

People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to experience cardiovascular death, heart attack or stroke ...

Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable treatment for hypoglycaemia, which can occur when people with diabetes inadvertently take too much insulin.

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine targeting a chronic blood disorder.

The bills, which have advanced in the Senate, would require schools to take certain preventative measures to protect student ...

The company is still digging for efficacy signals among subpopulations in the CedLara trial, but has switched its attention to vurolenatide, an injectable glucagon-like peptide-2 (GLP-2 ...

The issuer is solely responsible for the content of this announcement.

A large clinical trial, co-led by researchers at the UNC School of Medicine, has shown that the popular weight-loss drug ...